224 related articles for article (PubMed ID: 30500018)
1. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
[TBL] [Abstract][Full Text] [Related]
2. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
3. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
[TBL] [Abstract][Full Text] [Related]
4. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Drummond DC; Noble CO; Guo Z; Hong K; Park JW; Kirpotin DB
Cancer Res; 2006 Mar; 66(6):3271-7. PubMed ID: 16540680
[TBL] [Abstract][Full Text] [Related]
5. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.
Zhang W; Wang G; Falconer JR; Baguley BC; Shaw JP; Liu J; Xu H; See E; Sun J; Aa J; Wu Z
Pharm Res; 2015 Apr; 32(4):1451-61. PubMed ID: 25355460
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
7. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
[TBL] [Abstract][Full Text] [Related]
8. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
9. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral Injection Administration of Irinotecan-Loaded Microspheres: In Vitro and In Vivo Evaluation.
Zhu S; Dou M; Huang G
AAPS PharmSciTech; 2018 Nov; 19(8):3829-3838. PubMed ID: 30280351
[TBL] [Abstract][Full Text] [Related]
11. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
[TBL] [Abstract][Full Text] [Related]
12. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.
Liu X; Jiang J; Chan R; Ji Y; Lu J; Liao YP; Okene M; Lin J; Lin P; Chang CH; Wang X; Tang I; Zheng E; Qiu W; Wainberg ZA; Nel AE; Meng H
ACS Nano; 2019 Jan; 13(1):38-53. PubMed ID: 30525443
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
[TBL] [Abstract][Full Text] [Related]
14. Redox-sensitive irinotecan liposomes with active ultra-high loading and enhanced intracellular drug release.
Wang T; He W; Du Y; Wang J; Li X
Colloids Surf B Biointerfaces; 2021 Oct; 206():111967. PubMed ID: 34256270
[TBL] [Abstract][Full Text] [Related]
15. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB
Wang Z; Chi D; Wu X; Wang Y; Lin X; Xu Z; Liu H; Sun J; He Z; Wang Y
J Control Release; 2019 Dec; 316():22-33. PubMed ID: 31676386
[TBL] [Abstract][Full Text] [Related]
17. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
18. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
[TBL] [Abstract][Full Text] [Related]
19. Liposomal formulations of prilocaine: effect of complexation with hydroxypropyl-ß-cyclodextrin on drug anesthetic efficacy.
Bragagni M; Maestrelli F; Mennini N; Ghelardini C; Mura P
J Liposome Res; 2010 Dec; 20(4):315-22. PubMed ID: 20109055
[TBL] [Abstract][Full Text] [Related]
20. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.
Haran G; Cohen R; Bar LK; Barenholz Y
Biochim Biophys Acta; 1993 Sep; 1151(2):201-15. PubMed ID: 8373796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
